House Rx Secures $25M in Series A Financing

house rx

House Rx, a San Francisco, CA-based health technology platform focused on improving affordability and patient access to specialty medications, secured $25m in Series A financing.

The round, which brought total funding raised to date to $30m, was led by Bessemer Venture Partners with participation from First Round Capital,, and

The company intends to use the funds for continued investments in its technology platform and scaling pharmacy operations.

Led by Ogi Kavazovic, CEO, Tesh Khullar, President, and Denali Cahoon, PharmD, Chief Pharmacy & Operating Officer, House Rx provides a technology platform and pharmacy service which enable specialty practices to offer medically-integrated dispensing, which means patients can receive both their physician and pharmacy care from one team, collaborating on a unified technology platform. The technology platform helps prescribers and pharmacists collaborate via one integrated system and includes built-in analytics to enable continuous improvement in operational efficiency and quality of care.

Since it launched in March 2021, House Rx has partnered with four medical specialty practices and 30 prescribers in California and Washington. The specialty medical practices that have already partnered with House Rx include Care Oncology Center, California; Sarcoma Oncology, California; Arthritis Northwest Washington; and Northwest Medical Specialties, Washington. 

The company currently has over 30 employees, who are mostly software engineers and pharmacy operations.